101. Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.
- Author
-
UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV - Institut de Duve, de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, Fenaux, Pierre, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV - Institut de Duve, de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, and Fenaux, Pierre
- Abstract
While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better overall survival (OS, p=.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast (p=.031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome.
- Published
- 2013